Table 2 Stratification analysis of risk genotypes with neuroblastoma susceptibility

Age, month

 ≤ 18

129/130

10/9

1.13 (0.44–2.89)

0.800

71/58

68/81

0.69 (0.43–1.10)

0.119

50/64

89/75

1.52 (0.94–2.46)

0.089

 > 18

234/317

29/17

2.31 (1.24–4.30)

0.008

117/132

146/202

0.82 (0.59–1.13)

0.223

96/151

167/183

1.44 (1.03-2.00)

0.032

Gender

 Females

167/213

24/12

2.55 (1.24–5.26)

0.011

87/98

104/127

0.92 (0.63–1.36)

0.686

70/101

121/124

1.41 (0.95–2.09)

0.089

 Males

196/234

15/14

1.28 (0.60–2.72)

0.529

101/92

110/156

0.64 (0.44–0.93)

0.020

76/114

135/134

1.51 (1.04–2.20)

0.032

Sites of origin

 Adrenal gland

87/447

6/26

1.19 (0.48–2.98)

0.712

37/190

56/283

1.01 (0.64–1.60)

0.958

37/215

56/258

1.25 (0.80–1.97)

0.329

 Retroperitoneal

151/447

16/26

1.82 (0.95–3.48)

0.072

85/190

82/283

0.65 (0.46–0.93)

0.017

57/215

110/258

1.61 (1.11–2.32)

0.011

 Mediastinum

107/447

13/26

2.10 (1.04–4.22)

0.038

53/190

67/283

0.85 (0.57–1.27)

0.421

46/215

74/258

1.34 (0.89–2.02)

0.161

 Others

15/447

3/26

3.50 (0.95–12.91)

0.060

11/190

7/283

0.43 (0.16–1.13)

0.086

6/215

12/258

1.69 (0.62–4.57)

0.305

Clinical stages

 I + II + 4 s

165/447

8/26

0.84 (0.37–1.89)

0.669

72/190

101/283

0.94 (0.66–1.34)

0.726

76/215

97/258

1.06 (0.75–1.51)

0.749

 III + IV

143/447

20/26

2.42 (1.31–4.47)

0.005

83/190

80/283

0.64 (0.45–0.91)

0.014

48/215

115/258

2.00 (1.36–2.93)

0.0004